Month: May 2024

AUSTIN, Texas, May 13, 2024 (GLOBE NEWSWIRE) — Astrotech Corporation (Nasdaq: ASTC) (the “Company” or “Astrotech”) reported its financial results for the third quarter of fiscal year 2024, which ended March 31, 2024. Financial Highlights & Recent Developments Astrotech’s consolidated balance sheet remains strong with $34.7 million in cash and liquid investments. Year-to-date revenue totaled $1.6 million and was generated by sales of TRACER 1000™ explosive trace detector (ETD), as well as recurring maintenance services and sales of consumables for the TRACER 1000. The increase in revenue from the prior fiscal year is primarily the result of new unit sales of the TRACER 1000, fulfilling both of the previously announced purchase orders received. Year-to-date gross margin increased to 45% from 37% through the third quarter...

Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF mutant cancers BOSTON, May 13, 2024 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2024. The Company also provided an update regarding its organization and pipeline. “We continue to execute thoughtfully and diligently on our clinical programs,” said Mark Manfredi, Ph.D., Chief Executive Officer of Ikena. “With the dedication of our hyper-focused team and strong balance sheet, we are well positioned to build value for our shareholders...

Earliest Seasonal Deployment Positions the Company for Record Growth BELGRADE, Mont., May 13, 2024 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported results for the first quarter ended March 31, 2024. The Company also reiterated its 2024 revenue and adjusted EBITDA guidance supported by the earliest seasonal deployment in company history. Highlights:Earliest seasonal deployment of Super Scooper and surveillance aircraft in company history leads to highest first quarter revenue and positions the company for another record year Completed a $9.8 million equity financing in April 2024 with participation and support from existing investors as well as members of the management team...

IRVINE, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Shimmick Corp. (NASDAQ: SHIM), a leading water infrastructure company, today announced financial results for the first quarter ended March 29, 2024. First Quarter 2024 and Recent HighlightsReported revenue of $120 million, which includes $90 million of Shimmick Projects revenue Reported a net loss of $33 million with an Adjusted EBITDA loss of $24 million Continue to work down legacy backlog with revenue of $23 million, a decline from $56 million last year with a negative gross margin of $11 million, reflecting increases in the estimated cost to complete and ongoing legal costs Announced the sale of the assets related to non-core foundation drilling projects and an equipment yard that will raise approximately $39 million and reduce future capital expenditures Backlog is over $1.0...

– On Track to Provide Topline Data from the Ongoing Pivotal Clinical Trial with Oxylanthanum Carbonate (OLC) in Q2 2024 – – Multiple Presentations on OLC and UNI-494 at Prominent, Upcoming Medical Meetings – LOS ALTOS, Calif., May 13, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the three months ended March 31, 2024, and provided a business update. “This is an exciting time for Unicycive as we progress towards the conclusion of our pivotal clinical trial for our lead asset oxylanthanum carbonate (OLC),” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “The trial is evaluating the tolerability, safety, and pharmacokinetics of...

BARTLETT, Tenn., May 13, 2024 (GLOBE NEWSWIRE) — SurgePays, Inc. (Nasdaq: SURG) (“SurgePays” or the “Company”), a technology and telecom company focused on the underbanked and underserved, today announced its financial results for the first quarter ended March 31, 2024. Management Commentary Chairman and CEO Brian Cox commented on the quarter’s results, “The first quarter of 2024 was highlighted by continued execution on our growth strategy and solid profitability. With a substantial cash balance of over $42 million and a full product suite, we believe we are well-positioned to become one of the country’s largest distributors of prepaid wireless and underbanked financial technology services. The uncertainty surrounding ACP funding sparked a refreshing sense of urgency to grow our business. We believe our strategic hires,...

Key progress on strategic initiatives and intellectual property sets the foundation for an expected improvement in results for the balance of the year. JACKSONVILLE, Fla., May 13, 2024 (GLOBE NEWSWIRE) — Duos Technologies Group, Inc. (“Duos” or the “Company”) (Nasdaq: DUOT), a provider of machine vision and artificial intelligence that analyzes fast moving vehicles, reported financial results for the first quarter (“Q1 2024”) ended March 31, 2024.First Quarter 2024 and Recent Operational HighlightsNotified of an award for an additional Railcar Inspection Portal (“rip®” or “RIP®”) system in a new industrial application environment. The contract is expected to be valued at approximately $2.7 million and installed in 2024. This addition to the Duos portfolio of RIPs currently deployed in North America expands the potential addressable...

Hemophilia Program: Ongoing registrational PRESent-2 and PRESent-3 studies of SerpinPC for the treatment of hemophilia B; PRESent-2 interim analysis planned in 2024 Orexin Agonist Program: Cleared IND and initiated Phase 1 first-in-human clinical trial of ORX750, a highly potent and selective OX2R agonist for the treatment of narcolepsy; Clinical proof-of-concept data in acutely sleep-deprived healthy volunteers planned in 2H of 2024 LockBody® Technology Platform: Ongoing Phase 1/2a study of LB101 (PD-L1xCD47) for the treatment of solid tumors Cash runway, extended by recent public offering, supports clinical plans through multiple data readoutsBOSTON and LONDON, May 13, 2024 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that...

Self-mined 1,057 bitcoin in Q1 2024, an 8.9% increase over Q4 2023, on a total installed hashrate of 8.0 EH/s. Q1 2024 revenue grows 82.2% over Q4 2023 to $42.4 million. Q1 2024 Non-GAAP Adjusted EBITDA increases 95.4% over Q4 2023 to $32.0 million. Paid down approximately $63.6 million of debt so far in 2024, demonstrating the power of low-cost, profitable operations. On track to reach ~10.2 EH/s in Q3 2024, with plans to grow to ~13.3 EH/s by Q1 2025. EASTON, Md., May 13, 2024 (GLOBE NEWSWIRE) — TeraWulf Inc. (Nasdaq: WULF) (“TeraWulf” or the “Company”), which owns and operates vertically integrated, domestic bitcoin mining facilities powered by 95% zero-carbon energy, today announced its unaudited interim financial results for the first quarter of fiscal year 2024 and provided an operational update. First Quarter 2024 GAAP...

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) — TMC the metals company Inc. (Nasdaq: TMC) (“TMC” or “the Company”), an explorer of lower-impact battery metals from seafloor polymetallic nodules, today provided a corporate update and first quarter financial results for the period ending March 31, 2024. Q1 2024 Financial Highlights$11.9 million cash used in operations for the quarter ended March 31, 2024 Net loss of $25.2 million and net loss per share of $0.08 for the quarter ended March 31, 2024 Total liquidity of approximately $49 million at March 31, 2024, inclusive of: Cash of $4.0 million The $25 million unsecured credit facility from an affiliate of Allseas Group SA with a maturity date of August 2025 The $20 million unsecured credit facility with a maturity date of September 2025 provided by our largest shareholder, ERAS Capital...